BioHarvest Sciences Inc. Common Stock cash flow to debt ratio of -51.23% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioHarvest Sciences Inc. Common Stock's free cash flow has decreased 0.65% from $-9.52M last year to $-9.58M, signaling decreasing performance

BioHarvest Sciences Inc. Common Stock's debt to equity ratio is 0.71, which means that the company's assets are unhealthy financed, signaling financial risk.

BioHarvest Sciences Inc. Common Stock's debt has decreased relative to shareholder equity from 10.39 last year to 0.71 today, signaling strengthened financials

BioHarvest Sciences Inc. Common Stock has a net cash position, so leverage is healthy.

BioHarvest Sciences Inc. Common Stock's interest coverage ratio is -0.91, which means that the company struggles to meet interest obligations, signaling financial risk.

BioHarvest Sciences Inc. Common Stock's profit margin has increased (-36.54%) in the last year from -51.27% to -32.54%, signaling increasing performance

BioHarvest Sciences Inc. Common Stock's short-term assets of $30.50M exceed its short-term liabilities of $7.68M

BioHarvest Sciences Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioHarvest Sciences Inc. Common Stock's return on equity of -88.01%, is lower than 15.00%, indicating bad performance

BioHarvest Sciences Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioHarvest Sciences Inc. Common Stock had positive net income in only 0 out of 5 years, indicating unstable earnings

BioHarvest Sciences Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

BioHarvest Sciences Inc. Common Stock has negative free cash flow, indicating cash burn

BioHarvest Sciences Inc. Common Stock's yearly earnings has increased -13.77% since last year from $-12.91M to $-11.13M, signaling increasing performance

BioHarvest Sciences Inc. Common Stock's yearly revenue has increased 37.00% since last year from $25.19M to $34.51M, signaling increasing performance

ROIC -14.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioHarvest Sciences Inc. Common Stock's 3-year revenue CAGR of 84.46% is positive, indicating growing revenue over the past 3 years

BioHarvest Sciences Inc. Common Stock had revenue growth in 5 out of 5 years, indicating consistent revenue performance

BioHarvest Sciences Inc. Common Stock had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioHarvest Sciences Inc. Common Stock has insufficient data to evaluate this check.

BioHarvest Sciences Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioHarvest Sciences Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioHarvest Sciences Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioHarvest Sciences Inc. Common Stock has insufficient data to evaluate this check.

BioHarvest Sciences Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioHarvest Sciences Inc. Common Stock has a price-to-book ratio of 2.07x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioHarvest Sciences Inc. Common Stock has a price-to-sales ratio of 1.35x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue